IBDEI021 ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2255,1,1,0)
 ;;=1^V10.51
 ;;^UTILITY(U,$J,358.3,2255,1,8,0)
 ;;=8^Hx Of Bladder Malignancy
 ;;^UTILITY(U,$J,358.3,2255,2)
 ;;=^295228
 ;;^UTILITY(U,$J,358.3,2256,0)
 ;;=V10.52^^23^177^9
 ;;^UTILITY(U,$J,358.3,2256,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2256,1,1,0)
 ;;=1^V10.52
 ;;^UTILITY(U,$J,358.3,2256,1,8,0)
 ;;=8^Hx Of Kidney Malignancy
 ;;^UTILITY(U,$J,358.3,2256,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,2257,0)
 ;;=V10.46^^23^177^29
 ;;^UTILITY(U,$J,358.3,2257,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2257,1,1,0)
 ;;=1^V10.46
 ;;^UTILITY(U,$J,358.3,2257,1,8,0)
 ;;=8^Hx-Prostatic Malignancy
 ;;^UTILITY(U,$J,358.3,2257,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,2258,0)
 ;;=V10.47^^23^177^32
 ;;^UTILITY(U,$J,358.3,2258,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2258,1,1,0)
 ;;=1^V10.47
 ;;^UTILITY(U,$J,358.3,2258,1,8,0)
 ;;=8^Hx-Testicular Malignancy
 ;;^UTILITY(U,$J,358.3,2258,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,2259,0)
 ;;=V10.49^^23^177^23
 ;;^UTILITY(U,$J,358.3,2259,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2259,1,1,0)
 ;;=1^V10.49
 ;;^UTILITY(U,$J,358.3,2259,1,8,0)
 ;;=8^Hx-Male Genit Malig Nec
 ;;^UTILITY(U,$J,358.3,2259,2)
 ;;=^295226
 ;;^UTILITY(U,$J,358.3,2260,0)
 ;;=V10.45^^23^177^24
 ;;^UTILITY(U,$J,358.3,2260,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2260,1,1,0)
 ;;=1^V10.45
 ;;^UTILITY(U,$J,358.3,2260,1,8,0)
 ;;=8^Hx-Male Genit Malig Nos
 ;;^UTILITY(U,$J,358.3,2260,2)
 ;;=^295223
 ;;^UTILITY(U,$J,358.3,2261,0)
 ;;=V10.3^^23^177^4
 ;;^UTILITY(U,$J,358.3,2261,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2261,1,1,0)
 ;;=1^V10.3
 ;;^UTILITY(U,$J,358.3,2261,1,8,0)
 ;;=8^Hx Of Breast Malignancy
 ;;^UTILITY(U,$J,358.3,2261,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,2262,0)
 ;;=V10.41^^23^177^15
 ;;^UTILITY(U,$J,358.3,2262,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2262,1,1,0)
 ;;=1^V10.41
 ;;^UTILITY(U,$J,358.3,2262,1,8,0)
 ;;=8^Hx-Cervical Malignancy
 ;;^UTILITY(U,$J,358.3,2262,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,2263,0)
 ;;=V10.42^^23^177^34
 ;;^UTILITY(U,$J,358.3,2263,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2263,1,1,0)
 ;;=1^V10.42
 ;;^UTILITY(U,$J,358.3,2263,1,8,0)
 ;;=8^Hx-Uterus Malignancy Nec
 ;;^UTILITY(U,$J,358.3,2263,2)
 ;;=^295220
 ;;^UTILITY(U,$J,358.3,2264,0)
 ;;=V10.43^^23^177^11
 ;;^UTILITY(U,$J,358.3,2264,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2264,1,1,0)
 ;;=1^V10.43
 ;;^UTILITY(U,$J,358.3,2264,1,8,0)
 ;;=8^Hx Of Ovarian Malignancy
 ;;^UTILITY(U,$J,358.3,2264,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,2265,0)
 ;;=V10.44^^23^177^18
 ;;^UTILITY(U,$J,358.3,2265,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2265,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,2265,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,2265,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,2266,0)
 ;;=V10.81^^23^177^2
 ;;^UTILITY(U,$J,358.3,2266,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2266,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,2266,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,2266,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,2267,0)
 ;;=V10.82^^23^177^25
 ;;^UTILITY(U,$J,358.3,2267,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2267,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,2267,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,2267,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,2268,0)
 ;;=V10.83^^23^177^31
 ;;^UTILITY(U,$J,358.3,2268,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2268,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,2268,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,2268,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,2269,0)
 ;;=V10.84^^23^177^6
 ;;^UTILITY(U,$J,358.3,2269,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2269,1,1,0)
 ;;=1^V10.84
 ;;^UTILITY(U,$J,358.3,2269,1,8,0)
 ;;=8^Hx Of Eye Malignancy
 ;;^UTILITY(U,$J,358.3,2269,2)
 ;;=^295242
 ;;^UTILITY(U,$J,358.3,2270,0)
 ;;=V10.85^^23^177^3
 ;;^UTILITY(U,$J,358.3,2270,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2270,1,1,0)
 ;;=1^V10.85
 ;;^UTILITY(U,$J,358.3,2270,1,8,0)
 ;;=8^Hx Of Brain Malignancy
 ;;^UTILITY(U,$J,358.3,2270,2)
 ;;=^295243
 ;;^UTILITY(U,$J,358.3,2271,0)
 ;;=V10.86^^23^177^26
 ;;^UTILITY(U,$J,358.3,2271,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2271,1,1,0)
 ;;=1^V10.86
 ;;^UTILITY(U,$J,358.3,2271,1,8,0)
 ;;=8^Hx-Malign Nerve Syst Nec
 ;;^UTILITY(U,$J,358.3,2271,2)
 ;;=^295244
 ;;^UTILITY(U,$J,358.3,2272,0)
 ;;=V10.88^^23^177^16
 ;;^UTILITY(U,$J,358.3,2272,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2272,1,1,0)
 ;;=1^V10.88
 ;;^UTILITY(U,$J,358.3,2272,1,8,0)
 ;;=8^Hx-Endocrine Malign Nec
 ;;^UTILITY(U,$J,358.3,2272,2)
 ;;=^295246
 ;;^UTILITY(U,$J,358.3,2273,0)
 ;;=238.0^^23^178^1
 ;;^UTILITY(U,$J,358.3,2273,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2273,1,1,0)
 ;;=1^238.0
 ;;^UTILITY(U,$J,358.3,2273,1,8,0)
 ;;=8^Bone and Articular Cartilage
 ;;^UTILITY(U,$J,358.3,2273,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,2274,0)
 ;;=238.1^^23^178^3
 ;;^UTILITY(U,$J,358.3,2274,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2274,1,1,0)
 ;;=1^238.1
 ;;^UTILITY(U,$J,358.3,2274,1,8,0)
 ;;=8^Connective and Oth Soft Tissue
 ;;^UTILITY(U,$J,358.3,2274,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,2275,0)
 ;;=238.2^^23^178^17
 ;;^UTILITY(U,$J,358.3,2275,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2275,1,1,0)
 ;;=1^238.2
 ;;^UTILITY(U,$J,358.3,2275,1,8,0)
 ;;=8^Skin
 ;;^UTILITY(U,$J,358.3,2275,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,2276,0)
 ;;=238.3^^23^178^2
 ;;^UTILITY(U,$J,358.3,2276,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2276,1,1,0)
 ;;=1^238.3
 ;;^UTILITY(U,$J,358.3,2276,1,8,0)
 ;;=8^Breast
 ;;^UTILITY(U,$J,358.3,2276,2)
 ;;=^81956
 ;;^UTILITY(U,$J,358.3,2277,0)
 ;;=238.4^^23^178^15
 ;;^UTILITY(U,$J,358.3,2277,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2277,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,2277,1,8,0)
 ;;=8^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,2277,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,2278,0)
 ;;=238.5^^23^178^6
 ;;^UTILITY(U,$J,358.3,2278,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2278,1,1,0)
 ;;=1^238.5
 ;;^UTILITY(U,$J,358.3,2278,1,8,0)
 ;;=8^Histiocytic and Mast Cells
 ;;^UTILITY(U,$J,358.3,2278,2)
 ;;=^267778
 ;;^UTILITY(U,$J,358.3,2279,0)
 ;;=238.6^^23^178^14
 ;;^UTILITY(U,$J,358.3,2279,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2279,1,1,0)
 ;;=1^238.6
 ;;^UTILITY(U,$J,358.3,2279,1,8,0)
 ;;=8^Plasma Cells
 ;;^UTILITY(U,$J,358.3,2279,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,2280,0)
 ;;=238.71^^23^178^4
 ;;^UTILITY(U,$J,358.3,2280,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2280,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,2280,1,8,0)
 ;;=8^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,2280,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,2281,0)
 ;;=238.72^^23^178^7
 ;;^UTILITY(U,$J,358.3,2281,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2281,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,2281,1,8,0)
 ;;=8^Low Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,2281,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,2282,0)
 ;;=238.73^^23^178^5
 ;;^UTILITY(U,$J,358.3,2282,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2282,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,2282,1,8,0)
 ;;=8^High Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,2282,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,2283,0)
 ;;=238.74^^23^178^9
 ;;^UTILITY(U,$J,358.3,2283,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2283,1,1,0)
 ;;=1^238.74
 ;;^UTILITY(U,$J,358.3,2283,1,8,0)
 ;;=8^Myelody Synd w/ 5q Deletion
 ;;^UTILITY(U,$J,358.3,2283,2)
 ;;=^334030
 ;;^UTILITY(U,$J,358.3,2284,0)
 ;;=238.75^^23^178^10
 ;;^UTILITY(U,$J,358.3,2284,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2284,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,2284,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,2284,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,2285,0)
 ;;=238.76^^23^178^11
 ;;^UTILITY(U,$J,358.3,2285,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2285,1,1,0)
 ;;=1^238.76
 ;;^UTILITY(U,$J,358.3,2285,1,8,0)
 ;;=8^Myelofibrosis w/Myeloid Metaplasia
 ;;^UTILITY(U,$J,358.3,2285,2)
 ;;=^334032
 ;;^UTILITY(U,$J,358.3,2286,0)
 ;;=238.77^^23^178^16
 ;;^UTILITY(U,$J,358.3,2286,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2286,1,1,0)
 ;;=1^238.77
 ;;^UTILITY(U,$J,358.3,2286,1,8,0)
 ;;=8^Post Transp Lymphoprolif d/o PTLD
 ;;^UTILITY(U,$J,358.3,2286,2)
 ;;=^336526
 ;;^UTILITY(U,$J,358.3,2287,0)
 ;;=238.79^^23^178^12
 ;;^UTILITY(U,$J,358.3,2287,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2287,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,2287,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue
 ;;^UTILITY(U,$J,358.3,2287,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,2288,0)
 ;;=238.8^^23^178^13
 ;;^UTILITY(U,$J,358.3,2288,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2288,1,1,0)
 ;;=1^238.8
 ;;^UTILITY(U,$J,358.3,2288,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,2288,2)
 ;;=^267779
 ;;^UTILITY(U,$J,358.3,2289,0)
 ;;=238.9^^23^178^8
 ;;^UTILITY(U,$J,358.3,2289,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2289,1,1,0)
 ;;=1^238.9
 ;;^UTILITY(U,$J,358.3,2289,1,8,0)
 ;;=8^Lymph/Hematopoietic Tissue NOS
 ;;^UTILITY(U,$J,358.3,2289,2)
 ;;=^267780
 ;;^UTILITY(U,$J,358.3,2290,0)
 ;;=239.0^^23^179^5
 ;;^UTILITY(U,$J,358.3,2290,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2290,1,1,0)
 ;;=1^239.0
 ;;^UTILITY(U,$J,358.3,2290,1,8,0)
 ;;=8^Digestive Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,2290,2)
 ;;=^267781
 ;;^UTILITY(U,$J,358.3,2291,0)
 ;;=239.1^^23^179^11
 ;;^UTILITY(U,$J,358.3,2291,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2291,1,1,0)
 ;;=1^239.1
 ;;^UTILITY(U,$J,358.3,2291,1,8,0)
 ;;=8^Respiratory Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,2291,2)
 ;;=^267782
 ;;^UTILITY(U,$J,358.3,2292,0)
 ;;=239.2^^23^179^2
 ;;^UTILITY(U,$J,358.3,2292,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2292,1,1,0)
 ;;=1^239.2
 ;;^UTILITY(U,$J,358.3,2292,1,8,0)
 ;;=8^Bone,Soft Tissue,Skin Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,2292,2)
 ;;=^267783
 ;;^UTILITY(U,$J,358.3,2293,0)
 ;;=239.3^^23^179^4
